You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

NICORETTE (MINT) Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Nicorette (mint) patents expire, and what generic alternatives are available?

Nicorette (mint) is a drug marketed by Haleon Us Holdings and is included in two NDAs.

The generic ingredient in NICORETTE (MINT) is nicotine polacrilex. There are thirty drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nicorette (mint)

A generic version of NICORETTE (MINT) was approved as nicotine polacrilex by P AND L on March 15th, 1999.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for NICORETTE (MINT)?
  • What are the global sales for NICORETTE (MINT)?
  • What is Average Wholesale Price for NICORETTE (MINT)?
Summary for NICORETTE (MINT)
Drug patent expirations by year for NICORETTE (MINT)
Recent Clinical Trials for NICORETTE (MINT)

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NYU Langone HealthPhase 1
Office of Dietary Supplements (ODS)Early Phase 1
National Center for Complementary and Integrative Health (NCCIH)Early Phase 1

See all NICORETTE (MINT) clinical trials

Pharmacology for NICORETTE (MINT)

US Patents and Regulatory Information for NICORETTE (MINT)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Haleon Us Holdings NICORETTE (MINT) nicotine polacrilex GUM, CHEWING;BUCCAL 018612-003 Dec 23, 1998 OTC Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Haleon Us Holdings NICORETTE (MINT) nicotine polacrilex GUM, CHEWING;BUCCAL 020066-003 Dec 23, 1998 OTC Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NICORETTE (MINT)

See the table below for patents covering NICORETTE (MINT) around the world.

Country Patent Number Title Estimated Expiration
Russian Federation 2007146992 ПРИДАНИЕ ВКУСА ЖЕВАТЕЛЬНЫМ РЕЗИНКАМ, СОДЕРЖАЩИМ ЛЕКАРСТВЕННОЕ СРЕДСТВО ⤷  Start Trial
Japan 5627851 ⤷  Start Trial
China 103784423 Flavoring of drug-containing chewing gums ⤷  Start Trial
Argentina 053731 AROMATIZACION DE GOMAS DE MASCAR QUE CONTIENEN FARMACOS ⤷  Start Trial
South Africa 200710905 Flavoring of drug-containing chewing gums ⤷  Start Trial
Spain 2516650 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Market Dynamics and Financial Trajectory for NICORETTE (MINT)

Last updated: February 19, 2026

What Are the Key Market Factors Influencing NICORETTE (MINT)?

NICORETTE (MINT), a nicotine replacement therapy (NRT), primarily targets adult smokers seeking cessation aids. It is marketed in various forms, including gum, lozenges, patches, and more recently, gums with flavored varieties such as MINT. The drug operates within the global tobacco harm reduction landscape, influenced by regulatory, consumer preference, manufacturing, and competitive forces.

Market Size and Growth:
The global NRT market was valued at approximately $1.76 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 7.3% through 2027, driven by increasing awareness of smoking-related health risks and rising tobacco control policies (Fortune Business Insights, 2022[1]).

Regulatory Environment:
Governments enforce regulations targeting smoking reduction, influencing NRT demand. US FDA approval for over-the-counter (OTC) NRTs facilitates sales growth. The European Medicines Agency (EMA) also permits OTC sales, subject to marketing authorizations. Regulatory restrictions on flavored tobacco products redirect consumer interest toward alternatives like nicotine gums and lozenges, positively impacting NICORETTE (MINT).

Consumer Trends:
There is a shift toward flavored NRT options, aligning with consumer preferences for MINT and other flavors. Flavored gums and lozenges see higher adoption among young adults and recent quitters. Awareness campaigns and public health initiatives reinforce demand.

Competitive Environment:
Leading brands include Nicorette, NicoDerm, and CVS Health Nicotine Gum. Nicorette maintains a dominant position due to extensive distribution networks and brand recognition. Entry barriers for new entrants involve regulatory approval, manufacturing scale, and consumer loyalty.

Distribution Channels:
NICORETTE is available via pharmacies, online retailers, and supermarkets. The expansion of online sales channels and direct-to-consumer marketing enhance market penetration, especially in North America and Europe.

How Does Media and Policy Affect NICORETTE's Market?

Media influences consumer perception. Campaigns highlighting health risks of smoking and benefits of NRT support product uptake. Policy trends favor the market; bans on flavored tobacco products in certain jurisdictions, while restricting some nicotine products, tend to channel consumers toward approved NRT options like NICORETTE.

Impact of Regulatory Changes:

  • The US FDA's current approach permits OTC sales of NRTs, including MINT-flavored variants.
  • The EU’s Tobacco Products Directive (TPD) restricts flavored tobacco but allows NRTs, which benefits NICORETTE's market position in Europe.
  • Potential future regulations targeting flavored nicotine products could impact sales if restrictions are expanded.

What Are the Financial Trends for NICORETTE (MINT)?

Historical Revenue and Growth:
NICORETTE’s parent firms typically report annual revenues in the hundreds of millions. For example, GSK’s (GlaxoSmithKline) consumer health division, which includes NICORETTE, generated approximately £4.4 billion in 2022; NRT sales contributed a significant share (GSK Annual Report, 2022[2]).

Pricing Strategy:
NICORETTE's premium pricing reflects brand strength and formulation innovation. Average retail prices for NICORETTE MINT gum range from $4.50 to $6.00 per pack (10-20 pieces). Margin structures vary by distribution channel but are estimated at 40-50% gross margin.

Market Penetration and Revenue Forecasts:

  • Sales growth in mature markets (North America, Europe) remains steady, supported by smoking bans and health awareness campaigns.
  • Emerging markets exhibit growth potential, particularly where regulatory barriers lower.
  • Analysts project NICORETTE revenue to grow at a CAGR of 5-8% over the next five years, assuming stable regulatory conditions and consumer preferences (Market Watch, 2023[3]).

Investment and R&D:
R&D investments aim to optimize flavors, delivery methods, and compliance with new regulations. Launches of new formulations with extended duration or lower nicotine release are anticipated to sustain consumer interest.

How Will Market and Financial Dynamics Evolve?

Market Trends:

  • Increased regulatory focus on youth access and flavored nicotine products may lead to restrictions, impacting flavored variants like MINT.
  • Growth of digital marketing and online sales channels will accelerate reach.
  • A rising shift toward personalized cessation programs could favor product innovation.

Financial Outlook:

  • Larger firms will leverage existing distribution channels to expand affectations and innovate on flavors and delivery forms.
  • Competitive pressures may moderate price increases but sustain high margins due to brand loyalty.
  • Global growth is anticipated in emerging markets with less stringent regulation.

Key Takeaways

  • NICORETTE (MINT) operates in a stable, growing global NRT market valued at approximately $1.76 billion in 2022, with a projected CAGR of 7.3%.
  • Regulatory policies favor OTC availability but may restrict flavored variants, potentially impacting sales volumes.
  • Consumer preference shifts toward flavored and discreet products support NICORETTE’s MINT offerings.
  • Revenue growth is expected to range 5-8% annually over the next five years, driven by product innovation, market expansion, and regulatory trends.
  • Competitive landscape remains consolidated with GSK’s NICORETTE leading, but price competition and regulatory changes pose risks.

FAQs

1. How might future regulations impact flavored NICORETTE products?
Tighter restrictions on flavored nicotine products, especially aimed at youth, could limit the availability or marketing of flavors like MINT, reducing sales volume in key markets.

2. What is the primary factor driving NICORETTE’s revenue growth?
Product innovation combined with expanding consumer awareness and regulatory support for OTC NRTs contribute primarily to growth prospects.

3. How does pricing influence NICORETTE’s market share?
Premium pricing maintains margins while competitive pricing in mass retail channels supports market penetration.

4. Which geographic regions hold the most growth potential?
Emerging markets in Asia and Latin America exhibit significant potential due to increasing tobacco control policies and growing health awareness.

5. What competitive threats does NICORETTE face?
Entry of private labels, new product formats, and potential regulatory bans on flavored NRTs pose ongoing threats.


References

[1] Fortune Business Insights. (2022). Nicotine Replacement Therapy Market Size, Share & Industry Analysis.

[2] GSK. (2022). Annual Report 2022.

[3] Market Watch. (2023). Tobacco Harm Reduction and NRT Industry Forecast.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.